Successful derivation and characteristics of xeno-free mesenchymal stem cell lines from human amniotic fluid generated under allogenic cord blood serum supplementation

Tissue Engineering and Regenerative Medicine

Volumn 8, Issue 2, 2011, Pages 216-223

  Phermthai, Tatsanee ^a   Odglun, Yuparat ^a   Chuenwattana, Prakong ^a   Julavijitphong, Suphakde ^a   Titapant, Vitaya ^a   Vantanasiri, Chanchai ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Amniotic fluid stem cells; Cord blood serum; Mesenchymal stem cells; Regenerative medicine; Xeno free

Indexed keywords

AMNIOTIC FLUID STEM CELLS; CORD BLOOD; MESENCHYMAL STEM CELL; REGENERATIVE MEDICINE; XENO-FREE;

BLOOD; STEM CELLS;

CELL CULTURE;

EID: 84876922420     PISSN: 17382696     EISSN: 22125469     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. R Quarto, M Mastrogiacomo, R Cancedda, et al., Repair of large bone defects with the use of autologous bone marrow stromal cells, N Engl J Med, 344, 385 (2001).
2. PH Warnke, ING Springer, J Wiltfang, et al., Growth and transplantation of a custom vascularised bone graft in a man, Lancet, 364, 766 (2004).
3. DR Diduch, LCM Jordan, CM Mierisch, et al., Marrow stromal cells embedded in alginate for repair of osteochondral defects, Arthroscopy-the Journal of Arthroscopic and Related Surgery, 16, 571 (2000).
4. B Assmus, V Schachinger, C Teupe, et al., Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI), Circulation, 106, 3009 (2002).
5. E Tateishi-Yuyama, H Matsubara, T Murohara, et al., Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial, Lancet, 360, 427 (2002).
6. EV Badiavas, V Falanga, Treatment of chronic wounds with bone marrow-derived cells, Arch Dermatol, 139, 510 (2003).
7. MS Tsai, JL Lee, YJ Chang, et al., Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol, Hum Reprod, 19, 1450 (2004).
8. P De Coppi, G Bartsch, Jr., MM Siddiqui, et al., Isolation of amniotic stem cell lines with potential for therapy, Nat Biotechnol, 25, 100 (2007).
9. J Kim, Y Lee, H Kim, et al., Human amniotic fluid-derived stem cells have characteristics of multipotent stem cells, Cell Prolif, 40, 75 (2007).
10. M Amit, V Margulets, H Segev, et al., Human feeder layers for human embryonic stem cells, Biol Reprod, 68, 2150 (2003).
11. RP MacDermott, MJ Bragdon, Fetal calf serum augmentation during cell separation procedures accounts for the majority of human autologous mixed leukocyte reactivity, Behring Inst Mitt, 122 (1983).
12. F Kievits, WJ Boerenkamp, P Ivanyi, H-2-dependent binding of xenogeneic beta 2-microglobulin from culture media, J Immunol, 140, 4253 (1988).
13. TA Selvaggi, RE Walker, TA Fleisher, Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions, Blood, 89, 776 (1997).
14. A Mackensen, R Drager, M Schlesier, et al., Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells, Cancer Immunol Immunother, 49, 152 (2000).
15. L Tuschong, SL Soenen, RM Blaese, et al., Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy, Hum Gene Ther, 13, 1605 (2002).
16. EM Horwitz, PL Gordon, WK Koo, et al., Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone, Proc Natl Acad Sci U S A, 99, 8932 (2002).
17. JL Spees, CA Gregory, H Singh, et al., Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy, Molecular Therapy, 9, 747 (2004).
18. A Shahdadfar, K Fronsdal, T Haug, et al., In vitro expansion of human mesenchymal stem cells: Choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability, Stem Cells, 23, 1357 (2005).
19. C Ellerstrom, R Strehl, K Moya, et al., Derivation of a xenofree human embryonic stem cell line, Stem Cells, 24, 2170 (2006).
20. N Stute, K Holtz, M Bubenheim, et al., Autologous serum for isolation and expansion of human mesenchymal stem cells for clinical use, Exp Hematol, 32, 1212 (2004).
21. BS Mallon, KY Park, KG Chen, et al., Toward xeno-free culture of human embryonic stem cells, Int J Biochem Cell Biol, 38, 1063 (2006).
22. K Rajala, B Lindroos, SM Hussein, et al., A defined and xenofree culture method enabling the establishment of clinical-grade human embryonic, induced pluripotent and adipose stem cells, PLoS One, 5, e10246
23. HE Broxmeyer, L Benninger, M Yip-Schneider, et al., Commentary: a rapid proliferation assay for unknown costimulating factors in cord blood plasma possibly involved in enhancement of in vitro expansion and replating capacity of human hematopoietic stem/progenitor cells, Blood Cells, 20, 492 (1994).
24. P Shetty, K Bharucha, V Tanavde, Human umbilical cord blood serum can replace fetal bovine serum in the culture of mesenchymal stem cells, Cell Biology International, 31, 293 (2007).
25. AC Lam, K Li, XB Zhang, et al., Preclinical ex vivo expansion of cord blood hematopoietic stem and progenitor cells: duration of culture; the media, serum supplements, and growth factors used; and engraftment in NOD/SCID mice, Transfusion, 41, 1567 (2001).
26. YM Kim, MH Jung, HY Song, et al., Ex vivo expansion of human umbilical cord blood-derived T-lymphocytes with homologous cord blood plasma, Tohoku J Exp Med, 205, 115 (2005).
27. SM Phadnis, MV Joglekar, V Venkateshan, et al., Human umbilical cord blood serum promotes growth, proliferation, as well as differentiation of human bone marrow-derived progenitor cells, In Vitro Cell Dev Biol Anim, 42, 283 (2006).
28. D Campioni, R Rizzo, M Stignani, et al., A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs, Cytometry B Clin Cytom, 76, 225 (2009).
29. T Phermthai, Y Odglun, S Julavijitphong, et al., A novel method to derive amniotic fluid stem cells for therapeutic purposes, BMC Cell Biol, 11, 79 (2010).